to treat adults with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with febrile neutropenia. The drug, also developed by Hanmi, was launched last month into a ...

Chemotherapy-induced neutropenia is a major risk factor for infection-related morbidity and mortality and an important dose-limiting toxicity in cancer treatment. The incidence of severe ...

Karius is proving it can add value during drug development as well ... test in determining the etiologic diagnosis of febrile neutropenia: results from a pilot study. Open Forum Infect.

Possible symptoms include recurrent infections, fever, chills ... Treatment for neutropenia includes medications and ...

Seres Therapeutics has received US Food and Drug Administration (FDA ... of antibiotic treatment and decreased incidence of febrile neutropenia for the therapy-treated subjects.